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Key Points 
Most elderly patients with cardiovascular disease have three or more other chronic conditions and thus 
are prescribed multiple medications. 
Polypharmacy at an elderly age predisposes the patient to adverse drug events and non-adherence, with 
resultant escalation of morbidity, mortality, and healthcare costs. 
This manuscript highlights optimization of drug prescription, medication management, and the role of 
patient goals of care in shared decision-making. 
 
  
Abstract  
Cardiovascular disease increases incrementally with age and elderly patients concomitantly sustain 
multimorbidities, with resultant prescription of multiple medications. Despite conforming with disease-
specific cardiovascular clinical practice guidelines, this polypharmacy predisposes many elderly 
individuals with cardiovascular disease to adverse drug events and non-adherence. Patient-centered 
care requires that the clinician explore with each patient his or her goals of care and that this shared 
decision-making constitutes the basis for optimization of medication management. This approach to 
aligning therapies with patient preferences is likely to promote patient satisfaction, to limit morbidity, 
and to favorably affect healthcare costs. 
 
1 Polypharmacy in Older Adults: Scope of the Problem 
The prevalence of cardiovascular disease increases incrementally with age [1]. The majority of patients 
with ischemic heart disease, stroke, heart failure, and atrial fibrillation have three or more other chronic 
conditions (see illustrative case in Table 1). Forty-four percent of men and 57% of women >65 years of 
age take five or more medications each week; in another report, 37% of men and 36% of women aged 
75–85 years take at least five prescription medications. Twelve percent of both elderly men and women 
take ten or more medications weekly; this includes prescription medications, over-the-counter 
preparations, and herbal products [2].  
Patients in the Medicare age population (13% of the population) take a third of all prescribed 
medications. As well, these people consume 40% of all over-the-counter medications. Some 
polypharmacy may result from a prescribing cascade; that is, medications given to treat adverse effects 
and not subsequently discontinued [3]. Polypharmacy is associated with an increase in healthcare costs, 
adverse drug events, drug interactions, medication nonadherence, a decrease in functional status, and 
geriatric syndromes [4]. Deprescribing—a complex issue that likely warrants a separate manuscript—is 
described in detail elsewhere [28], but importantly impacts the topics to be discussed subsequently: 
adverse drug events, medication adherence, medication management, and shared decision-making in 
older adults with cardiovascular disease and multiple chronic conditions.  
Deprescribing must be included in the roles of the primary physician, the pharmacist, the cardiologist, 
and the entire care team. It is ideally addressed at each transition of care and medication reconciliation. 
2 Adverse Drug Events (ADEs) in Older Adults and Their Increased Vulnerability to ADEs 
Adverse drug events (ADEs) account for more than 170,000 emergency room visits for elderly patients 
each year [5]. There is a sevenfold increased likelihood that these patients will be admitted to hospital 
as compared with younger patients. Sixty-seven percent of all ADEs are related to warfarin, insulin, oral 
antiplatelet agents, and oral hypoglycemics [6], with two thirds of these due to unintentional overdose. 
ADEs are the fourth leading cause of hospital admission for older adults and represent 25% of their 
hospital admissions. Altered mental status is a common component of presentation. Not surprisingly, 
the risk of ADEs increases exponentially as the medication list expands.  
Aging changes in body composition, drug metabolism and clearance contribute to altered drug 
pharmacokinetics. The physiologic changes of aging impact pharmacodynamics (drug–physiologic 
substrate interaction). As well, drug–disease interactions and drug–drug interactions result from 
polypharmacy. This includes prescription drugs, over-the-counter drugs, herbal medications, and dietary 
supplements. Owing to the underreporting or disregard of ADEs, the numbers cited may be an 
underrepresentation (Tables 2, 3, 4). 
3 Medication Non-Adherence: Scopeof the Problem 
 
Non-adherence has a significant impact on disease control, morbidity, mortality, and healthcare costs. 
Non-adherence costs the United States healthcare system over US$100 billion in avoidable costs 
annually [7]. Because of the importance of non-adherence as a global health issue, the World Health 
Organization (WHO) released a report, Adherence to Long-Term Therapies: Evidence for Action in 2003. 
The WHO proposed a five-dimensional model of adherence that incorporates social and economic 
factors, therapy-related factors, patient factors, condition-related factors, and health system or 
healthcare team factors as contributors to adherence [9]. Missing from this valuable model are issues 
predominating in older adults: factors relevant to individuals with a decrease in life expectancy, severity 
of comorbidities, impairment of function, and patient priority aligned care. Improving adherence would 
have a far greater impact on health than developing additional therapies, particularly for chronic 
diseases such as cardiovascular disease and hypertension; nonetheless, in the elderly patient with 
multimorbidities, adherence issues must be aligned with patient priorities and goals of care. After 
receiving a prescription, about 30% of patients are estimated to not fill the prescription (initial or 
primary nonadherence). 
In a study of 32,514 prescriptions written to 15,961 people in Quebec, Canada, 31.3% did not fill the 
prescription within 9 months. Of these prescriptions that were written, 86.7% were for new therapies 
and 13.3% were for a change in therapy. The mean age of patients in this study was 61.55 years, and 
there was a decreased risk of non-adherence with increasing age. The highest incidence of initial non-
adherence was for medications for coronary artery disease (CAD), headache, and depression, with 
51.3% of prescriptions for CAD going unfilled [9]. 
Higher cost, higher numbers of recent hospitalizations, and the severity of comorbid conditions were all 
associated with higher rates of non-adherence. 
Non-adherence is common, particularly for chronic, asymptomatic conditions such as hypertension and 
hyperlipidemia. Estimates for non-adherence range from 25 to 50%, depending on the condition, 
treatment, and the method to estimate adherence [10]. Self-reported non-adherence ranges from 33 to 
57% [11]. Cost-related nonadherence (CRN) is a particularly important factor as nonadherence may be 
related to additional disparities in care by racial/ethnic group and socioeconomic status and because it is 
a more modifiable factor. In data from the Medicare Current Beneficiary Survey, CRN was reported by 
11.5% of participants. Non-adherence has been associated with decreased quality of life, increased 
costs, and increased mortality [11, 12]. 
4 Factors Contributing to Medication Non- Adherence and Strategies to Improve Adherence 
Non-adherence [8, 13] may be related to problems with the healthcare system including a poor quality 
of provider-patient relationships, poor communication, lack of access to healthcare and lack of 
continuity of care. Patient–physician interactions may be an important modifier of patient non-
adherence. A survey of paired patient–physician respondents found that 61% of patients rarely or never 
discussed adherence with their physicians, and two-thirds of the patients had moderate or poor 
adherence. Although the physicians agreed that adherence was important, 67% were unaware of how 
often their patients missed medication [14]. Despite the potential role of the physician in promoting 
adherence, continuity of care with a physician was not associated with patient adherence to 
antihypertensive drugs among Medicare beneficiaries in a study of Part D and Medicare claims data 
[15]. Patients who used multiple pharmacies were more likely to be non-adherent [16]. Factors that 
have been more consistently associated with non-adherence include female gender, Hispanic or non-
White race, increased medication cost, increased dosing frequency, and using multiple different 
providers or pharmacies. Medication class has been a predictor as well, with some pharmacologic 
categories in a therapeutic class having less adherence due to side effects or other difficulties with 
administration (e.g., diuretics compared with other antihypertensive drugs). No consistent association 
with adherence has been shown for increasing age, and there is no association between the disease or 
disease risk level and adherence. 
The medical condition is also contributory, with asymptomatic chronic disease and lack of physical clues 
associated with non-adherence, as well as mental health disorders such as depression. The patient 
categories relate to physical impairments such as vision problems or impaired dexterity or dysphasia; 
cognitive impairment; and psychological/behavioral issues. While increasing age is not a risk factor for 
non-adherence, older patients have age related issues that may pose unique barriers to adherence. For 
example, sensory losses, dysphagia, loss of cognitive function, and physical decline are all more common 
at elderly age and would provide unique barriers to optimal medication adherence [17]. Further, 
therapies not aligned with patient priorities for care provide added barriers to adherence and 
consideration must be given to deprescribing. The data cited above are likely most applicable to older 
adults who have a substantial life expectancy, few comorbid conditions, and who are generally 
physically fit and functional. An important consideration is that patients in this study were just older 
than age 50 and the extrapolation to a truly elderly population may be problematic. The recommended 
pharmacologic management in the cardiovascular clinical practice guidelines is diseasespecific, whereas 
the recommendations for an elderly patient with multiple comorbidities must be concordant with the 
healthcare priorities of that individual patient. 
The therapy characteristics also contribute to non-adherence, particularly the complexity of the regimen 
and side effects. Socioeconomic/cultural contributions include low literacy, higher medication costs, 
poor social support, and attitudes/beliefs about medication [17]. 
Several strategies are available to increase adherence. These include reduction of medication cost, 
including the use of generic medications and lower co-pays and facilitating access to therapy such as 
better access to pharmacies, mail order, or assistance [18]. Simplification [19] of the dosing regimen 
such as once-daily dosing, convenient administration time, association with a clue such as meals, etc., 
are valuable strategies. Adherence aids, both low tech and high tech, include family help, pill boxes, 
calendars, alarms, and mobile applications. Of note, low-cost reminder aids have been shown to be less 
helpful than expected in improving adherence [20]. It is important to involve and educate the family and 
caregivers and to reinforce those therapies that are concordant with individual patient’s goals of care. 
Non-adherence in hypertension and cardiovascular disease is associated with adverse outcomes and 
increased healthcare costs. A study using claims data for patients with a recent myocardial infarction or 
known atherosclerotic disease demonstrated significant differences in major adverse cardiovascular 
events for up to 2 years based on being fully (C 80%), partially (C 40 to\80%), or non-adherent (\40%) to 
statins or angiotensin-converting enzyme inhibitors [21]. The association between non-adherence and 
outcome has varied by the measure used; one study showed that claims-based adherence measures of 
antihypertensive adherence were associated with cardiovascular events, but self-reported adherence 
was not [22]. A recent meta-analysis confirms the association between better adherence to b-blockers, 
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, and 
statins is associated with a lower risk of all-cause mortality, lower risk of cardiovascular mortality, lower 
risk of myocardial infarctions, and lower risk of hospitalization, using data pooled from ten studies 
including 106,002 patients with cardiovascular disease [23]. These data may be highly relevant for 
provider–elderly patient discussions; whereas mortality issues may be deemed less appropriate by some 
elderly patients, the lower risks of hospitalization are likely valued by most. 
5 Approaches to Optimizing Adherence in the Elderly Cardiovascular Disease Population 
Adherence is the extent to which patients follow recommendations or prescriptions. Adherence can be 
measured multiple ways and can be measured relatively easily, quickly, and in real-time clinical practice. 
Many studies of non-adherence use administrative claims or refill data to generate a numerical estimate 
of adherence. Most studies report the proportion of days covered (PDC), which is calculated with the 
days’ supply obtained by the patient in a specific period as the numerator and the number of days in the 
specific period as the denominator. Another method is the Medication Possession Ratio, which is a sum 
of the days’ supply obtained as the numerator divided by the number of days between the first and last 
prescription fill dates as the denominator. These methods capture different aspects of adherence than 
self-report, medication diaries, or pill-counting techniques, but there is reasonable correlation among 
the measures [24]. 
While for the most part older adults do well with adherence to medications, they are prescribed 
considerably more medications than younger patients. This more intense pharmacotherapy in older 
adults is largely due to the greater numbers of chronic diseases, especially cardiovascular disorders. 
Rigorously tested interventions are needed to assist elderly persons with medication adherence. 
Marcum et al. recently conducted an evidence-based review of randomized controlled trials of 
medication adherence and associated health outcomes in older adults (mean age of the study groups 
was C 65 years) from 1970 through June 2016 [25]. Included trials were those with medication 
adherence as a primary or secondary variable and a health outcome such as exacerbation of disease, 
health-related quality of life, disability, an economic endpoint, or death. Of the 3305 potentially eligible 
studies reviewed, only 12 fulfilled inclusion criteria (0.36%) and of these studies only three assessed 
cardiovascular disorders such as hypertension or heart failure. However, six of the 12 studies targeted 
adherence related to polypharmacy and it might be argued that many of those older adult patients had 
cardiovascular disorders. The interventions were classified into three groupings, namely behavioral or 
educational approaches (n = 3), pharmacist support (n = 7), and use of reminders or simplification 
strategies (n = 2). A key conclusion from this review is that there is a paucity of high-quality research 
(e.g., randomized controlled trials) that examined the association between medication adherence and 
relevant health outcomes in older adults, particularly those with cardiovascular disease. 
Among the more effective interventions within the Marcum review was a study in patients with heart 
failure by Murray et al. [26]. The Murray study involved 314 low-income patients ≥ 50 years of age who 
were followed for 1 year after randomization to usual care or intervention. 
The intervention had three basic components: patient education, therapeutic monitoring, and 
communication with providers. Special icon-based medication instruction materials stressed content, 
language, organization, and presentation of the medication information to participants in the 
intervention group. An icon or glyph such as the Ace of Hearts was placed on the ace-inhibitor 
medication container and that same icon inserted on the instructional materials provided to 
participants. Other cardiovascular medications targeted (and given unique icons) included angiotensin-
receptor blockers, b-blockers, calcium-channel blockers, diuretics, and spironolactone. Adherence was 
measured by electronic monitors on the prescription containers, self-report, and refill adherence. Health 
outcomes measured included health-related quality of life, exacerbation of heart failure requiring an 
emergency department visit or hospitalization, patient satisfaction, ADEs, and annual total direct costs. 
Compared with usual care, medication adherence improved in the intervention group, which was 
associated with reduced composite emergency department visits and hospitalization resulting in lower 
direct healthcare costs. Patient satisfaction also improved. There were trends favoring reductions in 
ADEs and improved health-related quality of life that were not statistically significant. Because the 
Murray study involved patients older than 50 years of age, it remains uncertain how much of these data 
can be extrapolated to a truly elderly population. 
There are few randomized controlled studies of medication adherence and associated health outcomes 
involving older adults with cardiovascular disease. Most of the effective studies in the review by 
Marcum et al. [25] involved behavioral/educational or pharmacist involved interventions such as the 
one conducted by Murray et al. [26]. The interventions were designed with attention to cognitive 
behavioral approaches and often involved tailoring to individual patient needs. Such interventions take 
considerable time for already overwhelmed health professionals and there is limited funding earmarked 
to subsidize their needed involvement. Automation will likely play an important future role in assisting 
patients with their medications; however, there are limited automation and informatics- driven 
solutions at this time. Many factors are at the root of poor medication adherence in the elderly such as 
inability of patients to manage multiple medications, polypharmacy often involving multiple prescribers, 
the cost of drugs, the lack of attention to health literacy, and the limited amount of time available to 
health professionals to address medication adherence problems in their patients. 
Future rigorously designed studies of medication adherence and health outcomes should consider these 
factors in the design of adherence interventions, including the effects of deprescribing. 
Adherence in cardiovascular disease is critical for disease maintenance and prevention of adverse 
outcomes, including emergency visits, hospitalizations, and mortality [10]. Recent data from the 
Medicare Part D program evaluating adherence in patients aged 65 years and older show a 26% non-
adherence rate to antihypertensive medications, with substantial variation by state and by racial/ ethnic 
groups. Adherence varied by class of medication, with higher non-adherence for diuretics than other 
antihypertensives [27]. A wealth of literature has supported the importance of adherence in patients 
with hypertension and with coronary artery disease. The optimal threshold for good adherence is not 
established, but many studies identify adherence rates of 80% or higher as being adherent, or fully 
adherent (as opposed to non-adherence or partially adherence for rates <80%). 
 
6 Medication Management in the Older Adult with Cardiovascular Disease 
Cardiovascular medicine has been at the forefront of advancing the scientific underpinnings of clinical 
medicine. Principally through the conduct of randomized clinical trials that have been shown to reduce 
morbidity and enhance survival in patients with cardiovascular disease, there are a plethora of therapies 
to potentially offer patients with cardiovascular disease. Such successes have led to medication 
regimens in the rapidly expanding population of older adults with cardiovascular disease, the majority of 
who (68%) also have multiple chronic conditions, that are increasingly long and complicated. 
Polypharmacy, as evidenced by the case study presented, is increasingly common and presents 
significant challenges to the optimal management of drug therapies in older adults with cardiovascular 
disease. Indeed, a recent analysis of Veteran Affairs (VA) patients over the age of 65 years in 2007 
showed that half of patients (50%) had one or more prescribing problems including potentially 
inappropriate medications for older adults based on Beer’s criteria, drug dosing, drug–drug interactions, 
drug–disease interaction, and high-risk drugs (warfarin, insulin, digoxin). Notably, chronologic age was 
not strongly associated with four of the five types of prescribing issues assessed and comorbid burden 
substantially increased risk only for drug–disease interactions and use of high-risk drugs. However, the 
number of drugs was consistently the strongest predictor of prescribing problems [28]; those patients in 
the highest quartile of medication use had a 6.6- to 12.5-fold greater risk of each type of prescribing 
problem compared with patients in the lowest quartile [17]. These data coupled with the recent report 
that demonstrates significant gaps in the guidelines for common cardiovascular disorders [29], which 
notes individuals aged 75 years and older have been markedly underrepresented in most major 
cardiovascular trials, and virtually all trials have excluded older adults with complex comorbidities and 
significant physical or cognitive disabilities. Accordingly, we have a limited database from which to draw 
upon in making critical decisions on drug therapy for the older adult and further research in this arena is 
desperately needed. 
 
7 Decision-Making in the Care of Older Adults with Multiple Chronic Conditions: Role of Patient Goals 
of Care in Shared Decision-Making 
Disease-specific and evidence-based guidelines are generally applicable to older adults with life 
expectancy >10 -years, few comorbid conditions, and who are fit and functional, as long as they are 
consistent with patient preferences. At the other end of the spectrum, de-escalation of treatment, 
palliative care, and symptom management are appropriate for those with\1–2 years of life expectancy 
and advanced/end-stage disease such as dementia, cancer, or heart failure. 
The uncertainty relates to those individuals who have a shorter than a decade life expectancy, an 
increasing number and severity of associated conditions, and an impairment of function, where patient 
priority aligned care is critical for the planning of pharmacotherapy [30]. It is in this population where 
deprescribing becomes an important component of care. 
Factors for consideration in deprescribing include the drug burden, with consideration of non-
pharmacologic therapies; symptoms suggesting adverse drug effects; high-risk drugs or combinations; 
ascertaining whether the benefits outweigh the harm; issues of the current benefit for disease and 
symptoms—is there unnecessary continuation as a consequence of a prescribing cascade [31]. 
Preventive therapies must be queried in the setting of limited life expectancy, with consideration of the 
time to benefit [32]. As well, it is important to identify whether the patient is actually taking the drug 
and the correct dosage of the drugs. 
Some patient goals of care may be to decrease symptoms and hospitalizations [33]; other patients may 
desire an increase in functional capacity and independence. Most value the maintenance of cognition 
and quality of life, whereas some value an improvement in survival. The importance is to individualize. 
8 Conclusions 
Cardiovascular disease increases incrementally with age. Older adults with cardiovascular disease who 
characteristically take multiple medications for multimorbidity face challenges of adherence and ADEs. 
Guideline-based medical management for cardiovascular disease is disease-specific; this differs 
markedly for elderly patients with multimorbidities where patient goals of care must align with 
medication management. Particularly for elderly individuals with limited life expectancy, a deprescribing 
approach, in consultation with the patient, is likely to ensure patient-preferred care. 
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Table 1. Case of an elderly woman with a complicated medical regimen 
Mrs. J is an 87-year-old African American woman with a history of coronary artery disease (CAD), atrial 
fibrillation, hypertension, diabetes mellitus, heart failure with reduced left ventricular ejection fraction and 
NYHA class III symptoms, chronic kidney disease stage 4, depression, anxiety, and osteoarthritis. She is allergic 
to ACE inhibitors which cause tongue swelling. Mrs. J is a widow who lives alone. 
She smokes 5–10 cigarettes per day and drinks two Manhattans each day. She presents to the office with 
complaints of occasional dizziness when standing up from a chair and when getting out of bed. Her blood 
pressure is 105/60 mmHg when she is seated, and it decreases to 80/40 mmHg when she is standing. Her vital 
signs are also significant for a heart rate of 64 bpm when she is seated and increasing to 96 bpm when she is 
standing. Her respiratory rate is 16 per min 
 
Mrs. J’s medication regimen includes 
Aspirin 325 mg po daily 
Isosorbide mononitrate 60 mg po daily 
Amlodipine 2.5 mg po daily 
Metoprolol XL 25 mg po daily 
Warfarin 5 mg on Mon, Wed, Fri and 7.5 mg on Tues, Thurs, Sat, Sun 
Potassium chloride 40 mg po BID 
Repaglinide 2 mg po BID 
Furosemide 40 mg po daily 
Metolazone 2.5 mg po daily 
Losartan 25 mg po daily 
Lanoxin 0.25 mg po daily 
Amlodipine 2.5 mg po daily 
Spironolactone 50 mg po daily 
Doxazosin extended release 4 mg po daily 
St. John’s Wort 
Alprazolam 0.25 mg po TID prn anxiety 
 
How to manage this patient 
Discontinue doxazosin and amlodipine. Reduce dose of isosorbide mononitrate. Hold losartan (resume for heart 
failure when able). Continue metoprolol for heart rate control. Ask her to check her blood pressure morning and 
evening (if she has a BP cuff) over the next 2 days and report results to you. Return to clinic for reassessment 
within 3 days 
Obtain basic metabolic panel including BUN, creatinine, and electrolytes. Discontinue metolazone 
Ask her to hold furosemide and spironolactone for 2 days. Reassess furosemide and spironolactone dosing, as 
well as potassium supplementation in light of CKD, once results of basic metabolic panel are available 
Discontinue lanoxin given limited benefit in heart failure and increased hazard in CKD 
Check blood sugar and HbA1c. She is on the highest dose of repaglinide and this may need to be decreased 
Taper alprazolam using deprescribing protocol and assess further for depression and anxiety. Consider SSRI or 
SNRI at time of follow-up depending on need 
Discontinue St. John’s Wort because of interaction with warfarin 
Consider discontinuation of aspirin given stable CAD 
Encourage smoking cessation and avoidance of alcohol 
Daily weights. Return to clinic for reassessment within 3 days or sooner for worsening symptoms 
 
ACE angiotensin-converting enzyme, BID twice daily, BP blood pressure, bpm beats per minute, BUN blood urea nitrogen, CAD 
coronary artery disease, CKD chronic kidney disease, NYHA New York Heart Association, po orally, prn when necessary, SNRI 
serotonin–norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TID three times daily 
 
Table 2. Physiologic change: adverse drug effects 
Aging physiologic change Drug ADEs 
Conduction system degeneration CCBs and β-blockers Bradycardia 
Arterial and ventricular stiffness NSAIDs Heart failure and fluid retention 
Baroreflex and balance Antihypertensives Falls and orthostatic hypotension 
Decreased thirst Diuretics Dehydration 
Gastric atrophy Anticoagulation GI bleeding 
ADEs adverse drug effects, CCBs calcium channel blockers, GI gastrointestinal, NSAIDs non-steroidal anti-inflammatory drugs 
 
Table 3. Drug–disease adverse events. Drugs relatively contraindicated in selected diseases 
Drug Disease 
β-blockers Asthma, COPD 
ACE-I, NSAIDs Renal insufficiency 
Glucocorticoids Diabetes 
Anticholinergics BPH, cognitive impairment 
CCBs Constipation 
Gastroesophageal reflux 
Warfarin Low albumin states (malnutrition) 
ACE-I angiotensin-converting enzyme inhibitor, BPH benign prostatic hyperplasia, CCBs calcium channel blockers, COPD chronic 
obstructive pulmonary disease, NSAIDs non-steroidal anti-inflammatory drugs 
 
Table 4. Drug–nutraceutical/ OTC interactions 
Herbal   Drug Effect 
St. John’s Wort Warfarin  
CCB  
Statins  
Amiodarone 
↑Bleeding 
↓Absorption/↑metabolism 
↓Levels (CYP3A4)  
Photosensitivity 
Gingko Biloba Warfarin  
CCB  
Statins 
↑Bleeding 
↑Absorption 
↑Levels (CYP3A4) 
Garlic HMG-CoA reductase inhibitors 
Aspirin, warfarin 
↑Levels (CYP3A4) 
↑Bleeding 
Ginseng CCB 
Digoxin 
Warfarin  
↑Absorption/↓metabolism 
↑Levels  
↓INR 
Vitamin E  Warfarin Bleeding 
NSAIDs Warfarin, aspirin 
ACE-I  
Steroids 
Bleeding 
Renal failure  
↓Na, volume retention 
Psyllium Aspirin ↓Absorption 
ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme 
A, INR international normalized ratio, NSAIDs non-steroidal anti-inflammatory drugs, OTC over the counter products, ↑ 
increase, ↓ decrease 
 
